Joseph Alvarnas, MD: What has been the role of health plans in the expansion of Medicaid?
John Fox, MD: I’m a clinician; I’m not an administrator. But I think we’ve been very welcoming of patients into the plan. We’re advertising, certainly, to attract patients to the plan. But I would say, from an economic vantage point, that it’s been a mixed bag. There are a number of things, as we were talking about earlier, that need to be fixed—that aren’t going to be fixed now—to ensure that health plans can remain on the market. I think that’s the biggest challenge right now: those fixes that will allow health plans to remain economically viable on the exchange marketplace.
The other thing that you brought up is access. Have we improved access? I’m not sure. We haven’t changed the number of physicians in the country. We haven’t changed the number of ER physicians. I think there was an expectation that, with the passage of the ACA, patients who were previously going to the emergency room for their care would now go to a primary care physician. Well, we didn’t increase the number of primary care physicians either. We certainly improved payment access, but I don’t know if we’ve improved clinician access under the ACA.
Joseph Alvarnas, MD: The DSH funds went away ostensibly because people were going to have access to primary care physicians. I also haven’t seen a wholesale expansion of nurse practitioners to provide that role or change in the scope of practice with legislative perspectives. So, I think the access issue is a genuine concern. From a political point of view—Elizabeth, we’ll start with you, but I encourage the others as well to help—we heard John raise the question that maybe one of the grievances is that issue. Is healthcare a right or is it a privilege? We’ve had other functional issues raised as to whether or not the law has actually been effective. If you were to characterize the grievances that led to the formulation of the Republican healthcare plan and then subsequently led to its rejection, what would those key issues be?
Elizabeth Carpenter: I think it’s a couple of things. You start, fundamentally, with the fact that the Republican Party has not aligned on what replacing the Affordable Care Act looks like. And so, on one side, you have a group of individuals in the Freedom Caucus saying, “This is Obamacare light. This doesn’t go far enough. We want to roll back a lot of those patient protections”—that we articulated earlier in this segment—“things like guaranteed issue; things like making sure that health plans cover the 10 essential health benefits; those types of reforms.”
And now, on the other hand, you have 20 Republican senators that represent states that expanded Medicaid. And so, some of the Medicaid provisions in the law were very troublesome. Members who have grown to accept and embrace much of the market weren’t comfortable with where the Freedom Caucus was taking the bill. Unfortunately for House Speaker Ryan and Republican leadership, the party is pulling the policies in the bill in opposite direction. And the question is if they can come together and find a policy that reflects both sides’ ideology.
Robert Carlson, MD: I’d like to make this a little bit more real. Recently, I had reason to send some letters to Congress and the Senate about the Affordable Care Act and the American Health Care Act and access was a major focus of that. We need to be sure that patients with preexisting conditions can continue to get affordable healthcare. We need to eliminate lifetime limits, so that people can get lifetime healthcare, and we need to be sure that the high-risk pools aren’t there so that patients can actually afford the healthcare. Healthcare that they can’t afford doesn’t help. One of the responses that I got from a staffer in one of the congressmen’s office was, “No patient with cancer has ever died because they didn’t have health insurance.” I’m sorry. I’m a practicing clinician. I have seen patients die because they couldn’t afford their healthcare, usually because they had no health insurance.
Joseph Alvarnas, MD: Me, too.
Robert Carlson, MD: Patients die if they don’t have health insurance, and that’s really what this boils down to. Are we—as a society, as a medical system, and as a culture—going to configure healthcare so that we recognize that we just are writing off some lives? Or are we going to recognize that healthcare is a right and that we, as a society, have a responsibility to figure out how to responsively deliver affordable healthcare to individuals? It boils down to that. I personally don’t care what it’s called, as long as I don’t have to watch people die because they don’t have a big bank account.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More